Epoetin Theta for Anemia in Cancer Patients
Author Information
Author(s): Tjulandin Sergei A MD, Bias Peter MD, Elsässer Reiner Dipl.Stat., Gertz Beate PhD, Kohler Erich PhD, Buchner Anton PhD
Primary Institution: Russian Cancer Research Center
Hypothesis
Epoetin theta is superior to placebo in treating anemia in cancer patients receiving platinum-based chemotherapy.
Conclusion
Epoetin theta is a safe and effective treatment for symptomatic anemia due to platinum-based chemotherapy in cancer patients.
Supporting Evidence
- Epoetin theta showed a complete hemoglobin response in 65.8% of patients compared to 20.3% in the placebo group.
- Epoetin beta was also effective, with a 71.2% response rate compared to placebo.
- The mean dose of Epoetin theta at complete response was lower than that of Epoetin beta.
Takeaway
This study tested a new medicine called Epoetin theta to help cancer patients with anemia, and it worked better than a fake treatment.
Methodology
223 patients were randomly assigned to receive Epoetin theta, Epoetin beta, or placebo for 12 weeks, with the primary endpoint being the complete hemoglobin response.
Potential Biases
Potential bias due to the unblinding of the person administering the treatment.
Limitations
The study had a relatively small sample size and was limited to specific cancer types.
Participant Demographics
Patients were adults aged 18 and older with solid tumors and secondary anemia due to chemotherapy.
Statistical Information
P-Value
<0.0001
Confidence Interval
8.06 (3.89, 17.63)
Statistical Significance
p<0.0001
Digital Object Identifier (DOI)
Want to read the original?
Access the complete publication on the publisher's website